S10 E02: Yacin Marzouki on disrupting the traditional omnichannel model
EMJ GOLD: Pharma news, views and analysis
Release Date: 06/10/2025
S12 E04: Richard Shotton on behaviour, bias and better pharma marketing
EMJ GOLD: Pharma news, views and analysis
In this episode, Isabel sits down with Richard Shotton, founder of Astroten and author of Hacking the Human Mind, to explore how behavioral science can help the pharmaceutical industry communicate more effectively and influence meaningful change. In the show, Richard explains why understanding what really drives human behaviour matters more than relying on what people say. He discusses the power of social proof, trusted messengers and concrete storytelling, and shares why making the right behaviour easier can have a greater impact than simply making a stronger argument. Guest bio Richard...
info_outline
S12 E03: Rafal Kaminski on epilepsy, innovation and equity
EMJ GOLD: Pharma news, views and analysis
This content has been funded by Angelini Pharma. In this episode, Isabel sits down with Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, to explore how new science is reshaping brain health and what that means for patients. In the episode, Rafal reflects on his path into neuroscience and explains how Angelini is building its brain health pipeline, with a focus on epilepsy. He discusses the promise of new treatment approaches, the role of partnerships in driving progress and why better care depends on more than medicine alone. Guest bio Rafal Kaminski is Chief Scientific Officer at...
info_outline
S12 E02: Rethinking multiple sclerosis care: The future of MS
EMJ GOLD: Pharma news, views and analysis
In Part 3, Hideki Garren, Roche, shares a hopeful vision for slowing, stopping and ultimately preventing multiple sclerosis. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill Therapeutics, which he...
info_outline
S12 E02: Rethinking multiple sclerosis care: Challenging old frameworks
EMJ GOLD: Pharma news, views and analysis
In Part 2, Hideki Garren, Roche, discusses the challenge of measuring MS progression and the importance of better data, imaging and patient insight. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma, including senior roles at Roche, where he led global neuroimmunology development. Prior to this, Hideki served as Chief Medical Officer at Prothena Biosciences and held board and leadership roles at Coya Therapeutics, Novartis, and Bayhill...
info_outline
S12 E02: Rethinking multiple sclerosis care: From curiosity to care
EMJ GOLD: Pharma news, views and analysis
This week, Isabel sits down with Hideki Garren, Senior Vice President and Global Head of Clinical Development, Neurology, Roche, to explore how our understanding of multiple sclerosis is changing and what that means for patients. In Part 1, Hideki reflects on his path into neurology and explores the shift in how multiple sclerosis is understood, from relapses to ongoing progression. Guest bio Hideki Garren is Senior Vice President and Global Head of Clinical Development, Neurology, Roche, appointed in September 2024. He brings extensive leadership experience across biotech and pharma,...
info_outline
S12 E01: The 2026 pharma forecast: Unknowns and personal goals
EMJ GOLD: Pharma news, views and analysis
In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they’re working towards in 2026. Speaker bios Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Senior Vice President of European Markets, BMS Emma oversees Bristol Myers Squibb’s operations across 19 countries of Europe, bringing extensive global leadership experience spanning Europe, Asia,...
info_outline
S12 E01: The 2026 pharma forecast: Opportunities and threats
EMJ GOLD: Pharma news, views and analysis
As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year’s pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women’s health, alongside the key threats that could slow progress. Speaker bios Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are...
info_outline
S11 E05: Pharma’s year in review 2025
EMJ GOLD: Pharma news, views and analysis
This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board, EMJ, Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, and omnichannel expert Yacin Marzouki, the conversation looks back on a year defined by both disruption and progress. Across the episode, the contributors share their perspectives on the biggest setbacks and standout successes of the past 12 months, from regulatory uncertainty and access challenges to...
info_outline
S11 E04: The gender health divide: Driving change
EMJ GOLD: Pharma news, views and analysis
In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too many women and why embedding sex- and gender-aware science from day one could accelerate fairer, more effective care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient...
info_outline
S11 E04: The gender health divide: Bias in practice
EMJ GOLD: Pharma news, views and analysis
In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinical trial exclusion continues to skew the science. Discover why representation isn't just a workforce issue: it’s a scientific necessity, and the first barrier we must dismantle to ensure better care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one...
info_outlineThis week on the podcast, the team are joined by omnichannel engagement expert Yacin Marzouki, who shares his strategies on how to make omnichannel work for both pharmaceutical companies and healthcare professionals.
Together, Yacin and Jade sit down in the studio to explore what it takes to harmonise omnichannel across an organisation, why content activation is still a major hurdle, how to make sure messaging truly resonates with HCPs and much more. Expect practical insights on operational excellence, the evolving role of AI and a fresh perspective on what success looks like across a product’s lifecycle.
A little more on EMJ GOLD’s guest…
Yacin Marzouki is a global omnichannel engagement lead on a mission to disrupt the industry’s approach to omnichannel. Within the pharmaceutical sector, he specialises in shaping seamless customer journeys, driving content activation and aligning global strategies with local execution. Yacin is dedicated to transforming brand plans into meaningful, measurable customer engagements, and is passionate about building high-performing, collaborative teams that deliver real impact.